Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submissi...
Source: businessinsider.com